The ubiquitin-mediated proteolytic pathway as a therapeutic area
- PMID: 9020379
- DOI: 10.1007/s001090050081
The ubiquitin-mediated proteolytic pathway as a therapeutic area
Abstract
Ubiquitin-mediated proteolysis is involved in the turnover of many short-lived regulatory proteins. This pathway leads to the covalent attachment of one or more multiubiquitin chains to target substrates which are then degraded by the 26S multicatalytic proteasome complex. Multiple classes of regulatory enzymes have been identified that mediate either ubiquitin conjugation or ubiquitin deconjugation from target substrates. Timed destruction of cellular regulators by the ubiquitin-proteasome pathway plays a critical role in ensuring normal cellular processes. This review provides multiple examples of key growth regulatory proteins whose levels are regulated by ubiquitin-mediated proteolysis. Pharmacological intervention which alters the half-lives of these cellular proteins may have wide therapeutic potential. Specifically, prevention of p53 ubiquitination (and subsequent degradation) in human papilloma virus positive tumors, and perhaps all tumors retaining wild-type p53 but lacking the retinoblastoma gene function, should lead to programmed cell death. Specific inhibitors of p27 and cyclin B ubiquitination are predicted to be potent antiproliferative agents. Inhibitors of IkappaB ubiquitination should prevent NFkappaB activation and may have utility in a variety of autoimmune and inflammatory conditions. Finally, we present a case for deubiquitination enzymes as novel, potential drug targets.
Similar articles
-
Kip1 degradation via the ubiquitin-proteasome pathway.Leukemia. 1997 Apr;11 Suppl 3:363-6. Leukemia. 1997. PMID: 9209391
-
Role of the ubiquitin-proteasome pathway in regulating abundance of the cyclin-dependent kinase inhibitor p27.Science. 1995 Aug 4;269(5224):682-5. doi: 10.1126/science.7624798. Science. 1995. PMID: 7624798
-
In vivo ubiquitination and proteasome-mediated degradation of p53(1).Cancer Res. 1996 Jun 1;56(11):2649-54. Cancer Res. 1996. PMID: 8653711
-
The ubiquitin-mediated proteolytic pathway: mechanisms of action and cellular physiology.Biol Chem Hoppe Seyler. 1994 Sep;375(9):565-81. doi: 10.1515/bchm3.1994.375.9.565. Biol Chem Hoppe Seyler. 1994. PMID: 7840898 Review.
-
The ubiquitin-proteasome pathway in cancer.Br J Cancer. 1998;77(3):448-55. doi: 10.1038/bjc.1998.71. Br J Cancer. 1998. PMID: 9472642 Free PMC article. Review.
Cited by
-
Activation of protein kinase C triggers its ubiquitination and degradation.Mol Cell Biol. 1998 Feb;18(2):839-45. doi: 10.1128/MCB.18.2.839. Mol Cell Biol. 1998. PMID: 9447980 Free PMC article.
-
Therapeutic targets for hypoxia-elicited pathways.Pharm Res. 1999 Oct;16(10):1498-505. doi: 10.1023/a:1011936016833. Pharm Res. 1999. PMID: 10554089 Review.
-
Integrative Bioinformatic Analysis of Transcriptomic Data Identifies Conserved Molecular Pathways Underlying Ionizing Radiation-Induced Bystander Effects (RIBE).Cancers (Basel). 2017 Nov 25;9(12):160. doi: 10.3390/cancers9120160. Cancers (Basel). 2017. PMID: 29186820 Free PMC article.
-
Cell cycle checkpoints as therapeutic targets.J Mammary Gland Biol Neoplasia. 1999 Oct;4(4):389-400. doi: 10.1023/a:1018770417964. J Mammary Gland Biol Neoplasia. 1999. PMID: 10705922 Review.
-
PDZ Domain-Containing Protein NHERF-2 Is a Novel Target of Human Papillomavirus 16 (HPV-16) and HPV-18.J Virol. 2019 Dec 12;94(1):e00663-19. doi: 10.1128/JVI.00663-19. Print 2019 Dec 12. J Virol. 2019. PMID: 31597772 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials
Miscellaneous